|5.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|1.||Medeiros, L Jeffrey: 55 articles (11/2015 - 02/2002)|
|2.||Gascoyne, Randy D: 50 articles (11/2015 - 01/2004)|
|3.||Press, Oliver W: 45 articles (11/2015 - 05/2002)|
|4.||Nakamura, Shigeo: 44 articles (11/2014 - 02/2002)|
|5.||Jaffe, Elaine S: 42 articles (11/2015 - 04/2002)|
|6.||Younes, Anas: 42 articles (11/2015 - 12/2002)|
|7.||Yoshino, Tadashi: 41 articles (09/2015 - 02/2002)|
|8.||Coiffier, Bertrand: 40 articles (11/2015 - 04/2002)|
|9.||Ohshima, Koichi: 40 articles (01/2015 - 01/2002)|
|10.||Ferreri, Andrés J M: 39 articles (11/2015 - 08/2003)|
|1.||rituximab (Mabthera)FDA Link
01/01/2015 - "Rituximab as a single agent is highly effective and tolerable in first-line treatment of primary MALT Ocular adnexal Lymphomas. "
01/01/2015 - "Additionally, prophylaxis was dramatically effective in preventing PCP in rituximab-received lymphoma patients, suggesting that rituximab should be recommended for these patients. "
07/01/2010 - "In conclusion, immunochemotherapy treatment dramatically improved the outcome of patients with nodal DLBCL; however, its effect was less in primary extranodal cases, so the prognosis of patients with nodal and extranodal lymphomas has been equalized in the rituximab era."
06/01/2010 - "However, the maintenance therapy in aggressive lymphomas most probably gives no further improvement in patients, who have received rituximab already in the induction treatment. "
10/01/2009 - "Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized. "
|2.||Doxorubicin (Adriamycin)FDA LinkGeneric
05/01/2002 - "The study suggests that, despite several reports of improved survival times with doxorubicin-based protocols, most veterinarians in first opinion practice in England treat canine lymphoma with COP."
06/11/2010 - "Doxorubicin (Dox) has demonstrated potent activity in treating malignant lymphomas but its therapeutic efficacy is hampered by induction of cardiotoxicity. "
05/01/2008 - "Adriamycin (ADR) is a potent chemotherapeutic agent, effective in the treatment of leukaemias, lymphomas and many solid tumours. "
10/15/1993 - "Serum concentrations were again determined in 32 dogs with lymphoma that were in complete remission 3 weeks after 1 dose of doxorubicin (30 mg/m2 of body surface, i.v.) and in 22 dogs that were still in complete remission 3 weeks after a fourth dose of doxorubicin. "
11/08/1981 - "For the lymphoid lymphoma with diffuse pattern, the prognosis is still bad although we obtained with adriamycin a better rate of complete remission. "
|3.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/01/1984 - "Best results of treatment were achieved with the T-lymphoma line L735 treated with Cyclophosphamide and Etoposid. "
05/01/1967 - "Complete lymphoma remission during cyclophosphamide therapy."
10/01/2000 - "Mice suffering from such lymphomas could not be cured with a regimen using high dose cyclophosphamide similar to many ALCL patients. "
01/01/2014 - "Efficacy of the drug administered in so-called lymphoma treatment protocol (4 x 375 mg/m2/week) has been shown not to be inferior to cyclophosphamide. "
10/01/2013 - "Information was obtained regarding signalment, lymphoma stage, concurrent diseases, cyclophosphamide doses administered, adverse effects (including SHC), remission rates, and outcomes. "
|4.||Methotrexate (Mexate)FDA LinkGeneric
01/01/2014 - "Methotrexate (MTX) is the single most effective agent for the treatment of primary central nervous system lymphoma. "
01/01/2008 - "Methotrexate (Mtx) is highly effective in lymphomas and crosses the blood-brain barrier. "
08/01/2002 - "Spontaneous complete remission of the lymphoma was achieved 14 months after withdrawing immune suppression with methotrexate."
07/01/2010 - "This study analyzed retrospectively the clinical efficacy of combined therapy consisting of high-dose methotrexate (MTX), administered at a dose of 4 g/m2 every 2 weeks (maximum of 4 courses), followed by whole-brain irradiation for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. "
06/01/2015 - "Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma."
|5.||Vincristine (Oncovin)FDA LinkGeneric
02/01/2013 - "Phase 1 comprised 36 dogs with the ABCB1 wildtype, including 26 dogs with lymphoma (5 Border Collies and 21 dogs representing 13 other breeds) treated with vincristine in a previous study; phase 2 comprised 10 additional Border Collies, including 3 that developed VAM and 7 with an unknown phenotype. "
01/01/2010 - "For the first time, this study demonstrates that perturbation of IKK-2 by ML120B leads to synergistic enhancement of vincristine cytotoxicity in lymphoma. "
10/10/2001 - "The aim of the present study was to determine the uptake and clearance characteristics of Tc-99m MIBI in vincristine-resistant lymphoma cell lines. "
06/01/2000 - "Finally she consulted a neurologist and was admitted to hospital for further diagnostic studies and continuation of treatment for her lymphoma in March 1998 with a provisional diagnosis of severe vincristine-induced neuropathy. "
01/01/2000 - "Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial."
|6.||Etoposide (VP 16)FDA LinkGeneric
03/01/1999 - "JLP119 B lymphoma cells underwent apoptosis after exposure to the topisomerase II inhibitor etoposide and this was dramatically reduced when the cells were cultured in the GC system. "
01/01/1999 - "Oral etoposide has proven to be active in and clearly beneficial for patients with previously treated lymphomas. "
09/01/1993 - "Chronic oral etoposide therapy is an effective regimen for patients with relapse or refractory lymphoma."
07/01/1985 - "In conclusion, etoposide is considered effective for malignant lymphomas."
02/01/1985 - "These results demonstrated that VP-16 administered as an oral capsule is effective against malignant lymphomas and suggested a lack of clinical cross-resistance to standard chemotherapeutic agents."
03/01/1980 - "Inhibitory antibodies could be removed by absorption with C3 H B lymphoma cells and upon elution from antibody-coated cells proved again highly effective in inhibiting CML. "
02/01/1983 - "Immunohistochemical approach with the antibodies was very helpful for diagnosis of malignant lymphomas. "
05/15/1996 - "The BCL1 lymphoma in Balb/c mice can be successfully treated with bispecific (anti-CD3 x anti-idiotype) antibodies (BSABs). "
04/01/2008 - "TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs. "
12/01/1987 - "Therefore, when these antibodies are used to determine the immunophenotype of malignant lymphomas, the B-cell nature can be predicted with great confidence only when two, preferably three or more, of the antibodies give positive results. "
|8.||Prednisone (Sone)FDA LinkGeneric
02/10/2015 - "Right atrial lymphoma: rapid relief of TV obstruction by prednisone."
11/01/1999 - "A favorable response of the subcutaneous induration to prednisone treatment does not exclude the diagnosis of lymphoma; therefore, it does not supersede the need of a pathological evaluation. "
09/01/1992 - "Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease-free survival for one third."
01/01/1990 - "We conclude that in this patient AILD and prednisone administration constituted favoring factors for the development of an extranodal lymphoma."
02/01/1984 - "Hypothalamic-pituitary-adrenal function in patients receiving intermittent high dose prednisone therapy for lymphoma."
09/01/2009 - "Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?"
04/01/2004 - "Fludarabine-based regimen is highly effective for indolent lymphoma with mild toxicity. "
09/01/2004 - "In summary, fludarabine has proven to be a safe and effective agent in the treatment of indolent lymphoma. "
05/15/1990 - "Fludarabine is an important new agent effective against macroglobulinemic lymphoma, and should be evaluated further in combination with other active modalities."
07/01/1998 - "We report four patients with relapsed or refractory follicular (three) and lymphoplasmacytic (one) lymphoma who achieved complete remission (CR) with fludarabine (FDR) lasting from 3.2 to 6 years. "
06/01/2007 - "Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas."
05/01/1978 - "Twenty-two percent of lymphoma patients in long-term remission continued to have diminished cellular immune responses to VZV antigen. "
11/01/2009 - "Efforts have, therefore, been made to develop alternative T cell based therapies, and there is growing evidence that adoptive therapy with T cells targeted to lymphoma-associated antigens may be a safe and effective new method for treating this group of diseases. "
08/01/2003 - "Promising results have suggested human leukocyte antigen (HLA) class II as potential target for antibody-based lymphoma therapy. "
09/01/1996 - "Common leucocytic antigen proved to be very useful in differential diagnosis with malignant lymphoma."
|1.||Drug Therapy (Chemotherapy)
01/01/2014 - "In our study, surgery as the primary modality therapy or as part of a multimodality therapy for primary breast lymphoma is associated with a higher rate of treatment failure, whereas a combination of chemotherapy and local radiation therapy provides the best results. "
02/01/2012 - "A study of 57 reported cases of primary vaginal lymphoma suggested that the most common histologic type was DLBCL, and most of patients were in a localized stage and responded well to combination of chemotherapy and radiation therapy. "
01/01/2013 - "Immediately after initiating chemotherapy for lymphoma, the patient's symptoms improved dramatically and the mediastinal lesion decreased in size. "
09/01/2007 - "In recent decades, following the introduction of effective chemotherapy, the prognosis of children with leukaemia and lymphoma has dramatically improved, but data reflecting further possible improvement achieved in the 1990s are scarce. "
05/01/2006 - "Median survival of affected patients has improved considerably with the use of highly active anti-retroviral therapy directed against human immunodeficiency virus, along with multi-agent chemotherapy, and outcome of such patients now approaches that of human immunodeficiency virus-negative patients with aggressive lymphoma. "
01/15/2005 - "Available evidence of the efficacy of radiotherapy in most clinical situations for lymphoma were identified through extensive literature reviews and treatment guideline searches. "
07/01/1994 - "Analysis of the first manifestation of lymphoma progression after radiotherapy in relation to the treatment portals demonstrated radiotherapy to be highly effective in achieving local control. "
03/01/2011 - "The ICD was re-sited before he proceeded to chest wall radiotherapy, which resulted in complete remission of the lymphoma. "
01/01/2008 - "Pelvic MRI and pathologic examination of the urinary bladder after radiotherapy showed that the lymphoma was in complete remission; however, she received retuximab therapy at a dose of 375 mg/m2/week, 8 times additionally, because of the reduced radiotherapy. "
01/01/2007 - "He was in complete remission till he presented in 2002 with extranodal marginal zone lymphoma of the parotid gland for which he underwent superficial parotidectomy and radiotherapy. "
08/01/2009 - "Refractory CNS lymphoma in patients with NHL carries a poor prognosis, with a median survival of 2 to 6 months; the most promising treatment, autologous stem cell transplant, can extend median survival from 10 to 26 months. "
12/01/2009 - "To evaluate the efficacy of allogeneic HSCT, optimal conditioning regimens and a clear graft-versus-lymphoma effect should be defined. "
11/01/2008 - "The demonstration of sustained complete remission following immunotherapeutic intervention provides direct evidence of a graft-versus-lymphoma effect against DLBCL."
05/01/2007 - "This case study illustrates how stem cell transplant offers complete remission of this type of lymphomas."
01/01/1997 - "However, the efficacy of purging may greatly differ between individual lymphomas, and complete eradication of contaminating cells from PBPC grafts may rarely be achieved with CD34+ selection alone."
|4.||Combination Drug Therapy (Combination Chemotherapy)
09/01/1988 - "Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtypes of non-Hodgkin's lymphomas. "
01/01/1991 - "Initial results from studies with third-generation combination chemotherapy regimens for the treatment of aggressive non-Hodgkin's lymphomas (NHL) demonstrated complete remission (CR) rates higher than those reported with first-generation regimens. "
01/01/2010 - "The latter was initially considered as stage IE primary pulmonary lymphoma and was treated with combination chemotherapy resulting in complete remission. "
04/01/1999 - "The first was a case of primary malignant lymphoma of the cervical spinal cord which had been previously treated with radiation to the spinal lesion and combination chemotherapies and entered complete remission. "
03/01/1998 - "Approximately 50% of patients with aggressive non-Hodgkin's lymphomas (NHL) achieve a complete remission (CR) and cure with combination chemotherapy. "
|5.||Stem Cell Transplantation
01/01/2000 - "Currently 10/11 patients are in complete remission, while 1 patient, affected by follicular centre lymphoma, is alive with disease 52 months from autologous stem cell transplantation. "
02/01/1998 - "Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index."
11/15/1997 - "We have conducted a pilot study to investigate the role of high-dose therapy and autologous bone marrow/stem cell transplantation (ASCT) during first complete or partial remission in 52 patients with poor-risk aggressive lymphoma. "
12/01/2006 - "A total of 10 lymphoma and myeloma patients, in remission following induction therapy and considered eligible for high-dose therapy and autologous stem cell transplantation, were included in the study. "
12/01/2010 - "Likewise, for patients with poor prognostic factors, such as a high NK lymphoma prognostic index, autologous stem cell transplantation during remission and additional treatments with central nervous system prophylaxis may be beneficial. "